source
- Trump administration’s MFN drug pricing deals may cut projected Medicare savings by up to 80%The White House announced "most-favored-nation" pricing agreements with 26 pharmaceutical companies, saying the contracts would lower drug costs for federal programs. The deals require companies to…
- Regulators Share Guidance for Effective Sponsor MeetingsRegulators from the U.S. FDA, the U.K. MHRA and other European agencies met to outline best practices for sponsor‑regulator interactions. They highlighted that transparency, open collaboration, at…